Statistics from Altmetric.com
On 1 September 2015, the UK became the world’s first country to introduce a novel meningococcal B vaccine (Bexsero) into its national childhood immunisation programme. Bexsero is the only market authorised meningococcal B vaccine in the UK. Meningococcal B strains accounts for ~80% of all laboratory confirmed cases of invasive meningococcal disease (IMD) in England and Wales.1 Bexsero is estimated to protect against 73%–88% of the meningococcal B strains causing invasive disease in England and Wales.2
After observing more instances of clinical instability in our immunised neonates following the introduction of the new …
Original reference: None
Contributors AM conceived the project. SS and DM were responsible for the data collection. Statistical input by AR.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.